What's happening
Live detector signal
Generated 12:12 ET
SLXN — Silexion Therapeutics Corp Ordinary Shares is up 12.6%, at 0.17, on $685.2K traded, 0.85× float rotation. Score 84. Primary driver: 85.5% float rotation. Supply intelligence: squeeze-prone · 100.
Get alerts on $SLXN
Halts, resumptions, new filings, and updated reports — in your inbox within minutes of the event.
Free · one email per event, no digests or spam · unsubscribe anytime · joins real followers
Free float
4.7M
2026-08-19
Shares out
14.5M
latest detail
Market cap
$2.2M
at ref price
Short interest
105.9%
2026-09-30
Float rotation
0.85×
latest snapshot
20d dollar vol
$8.2M
baseline
Gap quality
squeeze-prone · 100
live supply-pressure model
Supply factor
positive gap demand
detector reason
Supply factor
very tight float
detector reason
Supply factor
heavy float rotation
detector reason
Supply factor
high short interest
detector reason
This estimates whether a gap is clean, squeeze-prone, mixed, or supply-heavy using float, float rotation, short interest, market cap, split risk, and live volume. Registered resale/ATM exhaustion is a planned deeper parser layer.
2026-10-19 12:10 ETSignalSilexion Therapeutics Corp Ordinary Shares is up 12.6%, at 0.17, on $685.2K traded, 0.85× float rotation. Score 84. Primary driver: 85.5% float rotation. Supply intelligence: squeeze-prone · 100.
2026-09-308-KItem 7.01 — Regulation FD disclosure; Item 9.01 — Financial statements and exhibits SEC
2026-09-298-KItem 1.01 — Entry into a material definitive agreement; Item 3.02 — Unregistered sales of equity securities +1 more SEC
2026-09-288-KItem 7.01 — Regulation FD disclosure; Item 9.01 — Financial statements and exhibits SEC
2026-05-29Split1-for-10 reverse split logged
2026-05-13 08:00 ETFDA / ClinicalSilexion Therapeutics Announces Initiation of GMP Clinical Supply Manufacturing of SIL204 with Leading Global CDMO, and New Approval of Phase 2/3 Trial From Tel Aviv Sourasky Medical Center News
2025-12-02 08:00 ETFDA / ClinicalSilexion Therapeutics Receives Positive Feedback from German Health Authority on Design of Phase 2/3 Clinical Trial in Pancreatic Cancer News
2025-11-12 09:00 ETFDA / ClinicalSilexion Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update News
2025-09-11 07:00 ETFDA / ClinicalSilexion Therapeutics Reports Positive Preclinical Data Demonstrating SIL204’s Reach and Activity in Major Pancreatic Cancer Metastatic Sites Following Systemic Administration News
Latest detector signalscore 84